← Leaderboards
William L Redmond
Providence Portland Medical Center
$2,939,722
Attributed
$4,585,672
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.2M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,585,672 · 5
By mechanism
R01$2,952,871 · 1
R21$764,526 · 2
R00$710,098 · 1
K99$158,177 · 1
Top collaborators
- Brendan D Curti6 shared
Most similar at Providence Portland Medical Center
Same institution · by research overlap
- Brendan D Curti$3,242,071
- Bernard A Fox$5,302,432
- Walter J Urba$2,009,864
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsTumorT-LymphocyteCellsTumor ImmunityT Cell ResponsePhase I Clinical TrialsPharmaceutical PreparationsImmunotherapyImmuneInnovationCancer CellImmune SystemResponseTumor MicroenvironmentCell PhysiologyMediatingInsightMolecularBaseAntitumor EffectLeukocytesMetastatic MelanomaClinical Care
Grant awards (12)
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$1,205,769
R01 · FY2025 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$571,136
R01 · FY2024 · CA
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$582,888
R01 · FY2023 · CA
Elucidating the role of intratumoral microbiota on immunotherapy efficacy$191,278
R21 · FY2022 · CA · contact PI
Phase II Clinical Development of Galectin-3 Inhibition and Anti-PD-1: Immune Monitoring and Tumor Response$593,078
R01 · FY2021 · CA
Elucidating the role of intratumoral microbiota on immunotherapy efficacy$234,218
R21 · FY2021 · CA · contact PI
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma$185,992
R21 · FY2016 · CA
Ipilimumab plus a galectin-3 inhibitor for metastatic melanoma$153,038
R21 · FY2015 · CA
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler$227,038
R00 · FY2013 · CA · contact PI
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler$241,530
R00 · FY2012 · CA · contact PI
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler$241,530
R00 · FY2011 · CA · contact PI
Ox40 mediated co-stimulation overcoming tumor-induced CD8 T cell peripheral toler$158,177
K99 · FY2010 · CA · contact PI